sponsored links

Sutent Approved for Rare Pancreatic Cancer (HealthDay)

Sponsored Links

HealthDay – MONDAY, May 23 (HealthDay News) — U. S. Food and Drug Administration approval of Sutent (sunitinib) has been expanded to include people with neuroendocrine pancreatic cancer that is inoperable or has metastasized to other parts of the body.

View full post on Yahoo! News: Health News


Sponsored Links
You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

AddThis Social Bookmark Button

Leave a Reply

You must be logged in to post a comment.